Dr. Reddy's Laboratories (NYSE: RDY)
Dr. Reddy's Laboratories Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Dr. Reddy's Laboratories Company Info
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
News & Analysis
What Is an Emerging Market Economy?
2 Top Global Value Stocks to Buy Now
Don't want to pay too steep a price for high-quality stocks? Look abroad.
Why Is No One Talking About Dr. Reddy's Stock?
The large generics manufacturer's share price is up more than 35% over the past year.
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.
Is Dr. Reddy's Laboratories a Buy?
An Indian manufacturer of generic prescription drugs can accomplish what American counterparts cannot. Here's why.
Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
Dr. Reddy's Laboratories Ltd (ADR) Is Tanking Today -- Here's Why
The company's shares fall hard in the wake of reporting disappointing results.
3 Value Stocks Near 52-Week Lows Worth Buying
These value stocks may be down, but they're far from out.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.